PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Pieris Pharmaceuticals, Inc. (PIRS)
NASDAQ:AMEX Investor Relations:
ir.pieris.com
Company Research
Source: Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pieris Pharmaceuticals, Inc. (NasdaqCM: PIRS) (the “Company”) and Palvella Therapeutics, Inc. Upon completion of the proposed transaction, Pieris shareholders are expected to own approximately 18% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Pieris shareholders.If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-pirs/ to learn more.To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.View source ver
Show less
Read more
Impact Snapshot
Event Time:
PIRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PIRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PIRS alerts
High impacting Pieris Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PIRS
News
- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic MalformationsGlobeNewswire
- Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial OfficerGlobeNewswire
PIRS
Sec Filings
- 11/18/24 - Form 3
- 11/14/24 - Form SC
- 11/13/24 - Form 10-Q
- PIRS's page on the SEC website